UPCC 28921: A Phase I/IIa Open-label Multi-centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumours
Enrolling By Invitation
99 years or below
All
1 Location
Brief description of study
This study has a mono therapy arm and a combination therapy arm. The main purpose of the mono therapy arm is to test the safety and tolerability of ART4215 in humans. The main purpose of the combination therapy arm is to test ART4215 compared to and in combination with talazoparib.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research
-
Age: 99 years or below
-
Gender: All
Updated on
14 Jun 2023.
Study ID: 850528
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
